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Abstract
Extracellular matrix interactions play essential roles in normal physiology and many pathological
processes. While the importance of ECM interactions in metastasis is well documented, systematic
approaches to identify their roles in distinct stages of tumorigenesis have not been described. Here
we report a novel screening platform capable of measuring phenotypic responses to combinations
of ECM molecules. Using a genetic mouse model of lung adenocarcinoma, we measure the ECM-
dependent adhesion of tumor-derived cells. Hierarchical clustering of the adhesion profiles
differentiates metastatic cell lines from primary tumor lines. Furthermore, we uncovered that
metastatic cells selectively associate with fibronectin when in combination with galectin-3,
galectin-8, or laminin. We show that these molecules correlate with human disease and that their
*To whom correspondence should be sent: sbhatia@mit.edu.
AUTHOR CONTRIBUTIONS
N.E.R.F. and S.N.B. wrote the manuscript. N.E.R.F., M.M.W., and S.N.B. designed the studies. N.E.R.F. and D.F.B.M. designed and
produced the ECM microarrays. M.M.W. generated the initial cell lines. N.E.R.F. and M.J.X. performed the ECM microarray seeding.
J.M.L. designed and synthesized the hairpins and retroviruses. N.E.R.F. performed all other experiments and all data analysis. All
authors contributed conceptual advice and edited the manuscript.
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
NIH Public Access
Author Manuscript
Nat Commun. Author manuscript; available in PMC 2013 October 10.
Published in final edited form as:
Nat Commun. 2012 ; 3: 1122. doi:10.1038/ncomms2128.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
interactions are mediated in part by α3β1 integrin. Thus, our platform allowed us to interrogate
interactions between metastatic cells and their microenvironments, and identified ECM and
integrin interactions that could serve as therapeutic targets.
INTRODUCTION
Cancer metastasis is a poorly understood multistep process that results in 90% of cancer-
related deaths1–2. At the time of initial diagnosis, almost half of lung adenocarcinoma
patients have detectable metastases and the majority of the remaining half will relapse with
metastatic disease after surgical removal of the primary tumor and adjuvant chemotherapy3.
Despite the ominous nature of metastatic disease, the molecular mechanisms that drive each
step are poorly characterized and few effective therapies exist4. Recently, it has become
apparent that the tumor microenvironment dramatically impacts metastatic progression5.
Changes in cancer cell-extracellular matrix (ECM) interactions likely influence each stage of
the metastatic cascade, starting with the loss of basement membrane adhesion to
colonization of distant sites. Furthermore, alterations in matrix production and crosslinking
can promote metastasis6–8. Consequently, inhibiting interactions of tumor cells with their
microenvironments by targeting adhesion molecules is an area of active investigation9–10.
While a variety of techniques exist for studying microenvironmental interactions, it has been
challenging to date to interrogate the functional implications of specific cell-ECM
interactions in a high-throughput manner. Injection of metastatic cells into embryos
documented the anti-tumor effects of the embryonic microenvironment11–12, and coculture
studies have identified the roles of carcinoma-associated fibroblasts on tumor progression13.
ECM-coated transwells have been used to study the effects of small numbers of individual
candidate ECM molecules on 2D invasion14, and 3D collagen gels have been useful
particularly in the study of matrix metalloproteinase activity15. In vivo studies using gene-
targeted mice have documented the importance of several ECM molecules and their
receptors in transplant-based models of cancer and metastasis16–17. Each of these techniques
has documented key microenvironmental regulators of metastasis, but they have not allowed
an unbiased systematic evaluation of the role that ECM components play.
Cell-ECM interactions are particularly difficult to study due to their complexity of
synergistic and antagonistic interactions in vivo18. Experiments targeting integrins, a central
family of cell surface receptors that mediate ECM interactions, have implicated integrin-
ECM interactions as important regulators of cancer progression9,19–20. However, in addition
to adhesion, integrins regulate stress transmission and bidirectional signaling, and typically
bind multiple ECM molecules21. Furthermore, transmembrane collagens, syndecans, lectins,
carbohydrates, gangliosides, glycolipids, CD44, and dystroglycans are among a host of non-
integrin ECM receptors. Thus, techniques that allow the specific unbiased interrogation of
cell-ECM adhesion are required to directly query the diversity of potential interactions.
In this study, we describe a high-throughput platform capable of systematically uncovering
cell-ECM interactions, and use this method to characterize the global changes in ECM
adhesion in a model of cancer progression. We previously described a first-generation
platform that utilized robotic spotting technology to generate arrays with combinations of
five ECM molecules found in normal basement membrane and connective tissue22. Since
then, others have utilized similar platforms to investigate ECM responses23–26. While these
platforms have demonstrated feasibility of such approaches in physiologic processes such as
differentiation of stem cells, they have not yet been applied to increase our understanding of
disease states. Furthermore, their limited size (typically five different ECM molecules) has
prevented them from querying the diversity of ECM interactions present in the human body.
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Here, we present an expanded ECM microarray platform containing 768 unique pairwise
ECM molecule combinations expressed differentially in development, regeneration, and
disease including an expanded representation of proteoglycans and glycosaminoglycans
which are difficult to study through integrin manipulation alone, and apply them to
investigate changes in adhesion throughout metastatic progression. We have established a
highthroughput pipeline to generate these microarrays that utilizes liquid handlers for
mixing of source ECM, optimized cell-seeding devices, and automated image capture and
analysis. We studied the adhesion profiles of lung adenocarcinoma cell lines generated from
a genetically engineered mouse model where discrete stages of metastatic progression have
been defined, and correlated the findings with in vivo ECM distributions in mice and
humans with metastatic lung cancer27–29. This approach is easily extensible to other disease
states, ECM combinations, and phenotypic readouts.
RESULTS
Extracellular matrix microarrays to probe cell-ECM adhesion
To allow the unbiased study of the ECM adhesion characteristics of any cells-of- interest,
we developed a novel high-throughput platform. We expanded, automated, and optimized
our adhesion platform22–23 to include every single and pairwise combination of 38 unique
ECM molecules (Supplementary Table S1). Thus, these arrays contain 768 different
combinations in quintuplicate and 160 control spots, for a total of 4000 arrayed features. To
fabricate the arrays, the 38 ECM molecules and controls are transferred from a 96-well
source plate to two low-volume 384-well plates and mixed thoroughly using a robotic liquid
handler. These 384-well plates are then used as source plates for deposition of the matrix
combinations onto the slides by a DNA microarray spotter. Prior to deposition of the
molecules, slides are coated with a polyacrylamide hydrogel that is allowed to dry after
soaking to remove any unpolymerized monomer. The dehydrated hydrogel acts to entrap
molecules without requiring their chemical modification (Fig. 1a). Our data indicate that
molecules larger than ～10kDa can be robustly entrapped in the hydrogel (Fig. 1b), and we
verified their entrapment using NHS-Fluorescein labeling or antibody-mediated detection
after entrapment (Fig. 1c). Of the 38 molecules that we tested by these methods, all showed
excellent reproducibility and uniformity within the expected region of printing (Fig. 1c).
To measure cell-ECM interactions, cells are seeded onto the arrays in serum-free media and
allowed to adhere for 1.5 hours at 37°C (Supplementary Fig. S1a). To ensure uniform
seeding, the slides are agitated every fifteen minutes. Furthermore, the top surfaces of the
slides are held flush with the bottom of the plate through the use of a custom-designed
seeding device that employs a vacuum seal (Supplementary Fig. S1b and 1c). This device
minimizes seeding variability between experiments and avoids cell loss by preventing cells
from settling below the slide surface or on the backs of the slides. Uniformity of seeding
across individual arrays and between replicate arrays was confirmed using test slides
composed of only one matrix molecule. To quantify cells bound to each spot, nuclei are
stained according to conventional fluorescence staining protocols, and the slides are imaged
using an automated inverted epifluorescent microscope with NIS Elements software (Fig. 1d
and 2a). Large images are cropped to individual spots and indexed using MATLAB
(Mathworks), and adhesion is quantified using CellProfiler software to detect and count
nuclei (Fig. 2b)30. Subsequent image and data analysis is performed in MATLAB.
ECM microarrays identify distinct adhesion profiles
To uncover changes in the global adhesion profile of cancer cells during cancer progression
and metastatic spread, we analyzed a panel of murine lung adenocarcinoma cell lines
derived from non-metastatic primary tumors (TnonMet), primary tumors that metastasized
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(TMet), or lymph node (N) and liver (M) metastases (Supplementary Table S2)29. These cell
lines were derived from a genetically-engineered mouse model of metastatic lung
adenocarcinoma in which tumors were initiated in KrasLSL-G12D/+;p53flox/flox mice with
lentiviral-Cre vectors. The stable and random integration of the lentiviral vector allowed the
clonal relationship between the multifocal primary tumors and metastases to be
established29. Analysis of the adhesion profiles of these cell lines highlighted the diverse
adhesion of each line to different ECM combinations (Fig. 2c). Our analysis of these cell
lines revealed highly reproducible adhesion between replicate spots and arrays, confirming
the quantitative nature of the assay (Fig. 2d). We examined the profiles to interrogate
whether various populations exhibit enhanced adhesion to combinations of ECM molecules,
relative to the same molecules spotted in isolation. This analysis revealed that different
pairwisecombinations of ECM molecules result in additive, synergistic, and antagonistic
effects on adhesion. For example, for the TnonMet cell line shown in Figures 2c and 2e, many
molecules improve adhesion to collagen I, while others reduce cell binding in comparison to
the molecule in isolation (blue line, Fig. 2e). A similar range of responses was observed for
other molecules, including collagen IV and fibronectin (Figure 2e). These types of
combinatorial effects were present for many molecules and, while the specific patterns
varied, all cell lines tested exhibited examples of increased and reduced binding to various
ECM combinations. For each of the eleven murine lung adenocarcinoma cell lines tested,
distinct profiles that were highly reproducible across replicate slides were obtained (Fig. 2d).
We used the ECM microarrays to compare the adhesion profiles of populations from each of
the TnonMet, TMet, N, and M classes of cell lines. We applied unsupervised hierarchical
clustering analysis of the adhesion values in a manner analogous to clustering of gene
expression microarray data. Interestingly, all the cell lines derived from metastases (N or
M), save for one lymph node line, clustered independently from the cell lines derived from
primary lung tumors (TnonMet or TMet) (Fig. 3a). This result is particularly notable, since two
of the metastatic lines (393M1 and 389N1) were generated from metastases that originated
from two of the primary tumors (393T5 and 389T2, respectively), yet clustered more closely
to the other metastases than the lines derived from those primary tumors. Thus, there is a
conserved change in the ECM adhesion profile of cancer cells present in a metastatic site
versus those that remain in the primary tumor. Furthermore, this differential clustering was
not evident from unsupervised hierarchical clustering of the gene expression of these lines
(ref29 and Supplementary Fig. S2), suggesting that the metastasis-specific adhesion
phenotype provides a complementary, non-overlapping view of the molecular mediators that
influence metastatic progression.
Identification of metastasis-associated ECM molecules
In light of the hierarchical clustering results, we asked whether there were particular
combinations of molecules that are favored by metastatic cells rather than by cells from
primary tumors. Thus, we compared the average adhesion of the liver metastasis-derived
cell lines (M) for each ECM combination to the average adhesion of the TMet lines (Fig. 3b).
While many of the M lines exhibit elevated binding to combinations containing fibronectin,
pairings that combined fibronectin with any of galectin-3, galectin-8, or laminin had the
highest differential adhesion between line classes. To explore changes in adhesion that
specifically correlated with changes in metastatic progression, we compared the TMet cell
line 393T5 and the clonally-related liver metastasis-derived cell line 393M1. This pair of
lines was derived from a primary tumor and a metastasis that disseminated from that tumor,
as confirmed by examination of the lentiviral integration site 29. Furthermore, the
differential adhesion to the aforementioned ECM combinations was clear in both the group-
wise comparison (Fig. 3b) and in the direct comparison of this primary tumor-liver
metastasis pair (Fig. 3c).
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Collectively, the patterns observed suggest that combinations of molecules may play a more
significant role in the adhesion profile of a given population than the tendency to bind to any
of the ECM molecules alone. Interestingly, the trend towards increased binding to
fibronectin/galectin-3, fibronectin/laminin, and fibronectin/galectin-8 combinations was
consistent across tumor progression when we compared the average adhesion of all TnonMet,
TMet, N, and M cell lines (Fig. 3d). Binding to these molecules, when presented alone,
showed minimal (fibronectin) or no trend (laminin, galectin-3, and galectin-8) across the
four groups of cell lines (Supplementary Fig. S3a, red bars). When in combination, however,
these pairs demonstrate enhanced effects that exceed the additive values of their individual
adhesion. In contrast, other combinations demonstrated a reduced adhesion trend in
relatively more metastatic populations, including a variety of collagens and osteopontin
(Supplementary Fig. S3a–c). Taken together, these data suggest that adhesion to fibronectin
in combination with any of galectin-3, galectin-8, or laminin is highly associated with tumor
progression in this model system.
We also noted that some combinations of molecules appear to elicit antagonistic effects on
adhesion. We looked more closely at the adhesion profile of the M line 393M1
(Supplementary Fig. S4a) and observed that, while the metastasis-associated molecules
laminin, galectin-3, and galectin-8 all increase adhesion to fibronectin, other molecules
appeared to decrease adhesion to it (Supplementary Fig. S4b). In vitro adhesion assays using
co-adsorbed ECM to multiwell polystyrene plates confirmed that the addition of these
molecules does indeed decrease the adhesion of this line to fibronectin (Supplementary Fig.
S4c). Collectively, the existence of both synergistic and antagonistic effects highlights the
importance of investigating combinations of ECM molecules rather than isolated
components.
ECM molecules are present in sites of endogenous tumors
Next we sought to correlate our in vitro adhesion profiles with ECM expression in vivo. To
investigate whether the identified ECM molecules may be important in natural
tumorigenesis, organs containing primary autochthonous tumors and their metastases were
resected from KrasLSL-G12D/+;p53flox/flox mice and stained. Trichrome staining of lungs with
extensive tumor burden revealed a significant presence of ECM deposition in the tumor-
bearing lung (Supplementary Fig. S5a and ref 31). Previously, we found that primary tumors
that have acquired the ability to metastasize (TMet tumors) upregulate the chomatin-
associated protein Hmga229. Therefore, we used Hmga2 immunohistochemistry in addition
to histological characteristics to identify areas of highly aggressive cancer cells
(Supplementary Fig. S5a). As anticipated, primary lung tumors were positive for collagen I
(black arrowheads), collagen VI (open black arrowheads), and osteopontin (red arrowheads),
with the most intense staining overlapping with the high-grade tumor areas (Supplementary
Fig. S5a and S5c). In particular, osteopontin staining strongly co-localized with Hmga2pos
regions, suggesting that increased osteopontin production is associated with metastatic
primary lung tumors. Furthermore, little to no laminin, galectin-3, or galectin-8 staining was
detected in the primary tumors (Fig. 4). Interestingly, fibronectin staining in the tumor was
strong, revealing a correlation between increasingly metastatic populations and the presence
of fibronectin early in the metastatic cascade (Fig. 4).
We next asked whether the lymph node and distant organ metastases contained the
metastasis-associated ECM molecules. Again, trichrome staining revealed the presence of
significant matrix deposition within the lymph nodes (Supplementary Fig. S5b). As
expected, the entirety of the lymph node tumors were histologically high-grade and were
Hmga2pos (Supplementary Fig. S5b). There was also clear expression of all four of the
metastasis-associated molecules (fibronectin, laminin, galectin-3, and galectin-8) within the
lymph node metastases (Fig. 4). Furthermore, there was essentially no collagen I or collagen
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VI (Supplementary Fig. S5c). Interestingly, osteopontin was present in the metastases
(Supplementary Fig. S5c) and had its highest expression along the invasive front
(Supplementary Fig. S5a,d).
We also examined common metastatic sites for the presence of the metastasis-associated
molecules (Fig. 4). Both galectin-3 and galectin-8 were distinctly visible in these sites.
Laminin and fibronectin both appeared to line the sinusoids of the livers of the mice and
were also present in the metastases formed there. To determine whether these differences
between the primary and metastatic sites were due to altered matrix production by the tumor
cells, we performed immunoblots on the 393T5 and 393M1 TMet and M cell lines. While the
M line showed slight increases in fibronectin and laminin production compared to the TMet
line, production of both galectins was constant (Fig. 5a). Furthermore, collagen I production
was constant, and osteopontin production was actually increased in the M line. Taken
together, these data suggest that the ECM microarrays identified molecules that were found
within the physiologically relevant sites of mice bearing autochthonous tumors, and that
production of these molecules is not solely performed by the tumor cells present in those
sites.
Integrin surface expression correlates with ECM binding profiles
We noted that comparisons of adhesion trends on our ECM arrays did not necessarily
correlate with transcriptional profiles of the cognate integrins (Fig. 5b). Thus, to correlate
our findings with the presence of receptors for these metastasis-associated ECM molecules,
we examined the clonally-related pair of representative TMet and M cell lines for surface
expression of their cognate integrins. While the mRNA expression patterns did not show
significant upregulation of the metastasis-associated integrins in the M line by gene
expression microarray (Fig. 5c), flow cytometry analysis of the integrin subunits
corresponding with either the primary tumor-associated molecules or metastasis-associated
molecules revealed that the receptor expression trends were consistent with the observed
binding patterns. Specifically, integrin subunits known to bind fibronectin (α5 and αv),
laminin (α6 and α3), and galectins (α3) were all more prevalent on the metastasis-derived
line, while those associated with collagens (α1 and α2) were relatively higher on the
primary tumor-derived line (Fig. 6a). Nonetheless, the surface expression trends were
consistent for the other TMet and M lines as well (Supplementary Fig. S6a). Furthermore,
within a given cell line, we observed relatively homogeneous surface expression of the
metastasis-associated integrins (Supplementary Fig. S6b) suggesting that variations in
adhesion between lines are due to global increases in surface receptor expression, rather than
binding patterns of select subpopulations.
Immunohistochemistry revealed that these integrins were also present in the metastases of
mice bearing autochthonous tumors, but not the adjacent tissue (Fig. 6b). The finding that
the transcriptional levels of the integrins do not agree with the adhesion trends suggests that
post-transcriptional regulation, post-translational modifications such as altered
glycosylation, or alterations in activation state of the integrins are likely responsible for the
changes in adhesion. Thus, by utilizing our platform that investigates specific ECM binding
rather than receptor gene or protein expression, we are able to identify candidate ECM
interactions that might otherwise have been overlooked.
Integrin α3β1 mediates adhesion and seeding in vitro and in vivo
To examine which candidate receptor/ECM interactions may participate in the observed
binding patterns, we performed in silico network mapping of the metastasis-associated ECM
molecules using GeneGO software (Metacore) of manually curated molecular interactions.
We generated a network map that we termed the Lung Adenocarcinoma Metastasis (LAM)
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network that has a greatest disease association with ‘Neoplasm Metastasis’ (P = 1.094 ×
10−45, hypergeometric test, Fig. 7a, Supplementary Fig. S7). A network generated using the
same parameters but with the primary-tumor-associated molecules did not exhibit any
disease association with metastasis (Supplementary Fig. S8). Analysis of the LAM network
identified integrin α3β1 as the surface receptor with the greatest number of edges (Fig. 7a).
Based on this finding, we performed a knockdown of both the α3 and β1 subunits (ITGA3
and ITGB1, respectively) using short-hairpin-mediated RNA-interference (Supplementary
Fig. S9). Knockdown of these genes in the metastatic line, 393M1, resulted in reduced
adhesion to the metastasis-associated molecules in vitro when compared to the control
hairpin targeting the firefly luciferase gene (Fig. 7c).
We next assessed whether this integrin dimer plays a role in metastatic seeding in vivo.
Thus, we conducted experimental metastasis assays by intrasplenic injection of 393M1-shα3
or 393M1-shFF cells into wild type mice, and monitoring for liver tumor formation. We
found that mice injected with the 393M1-shα3 cells formed fewer tumor nodules than the
controls (Fig. 7d–f). Taken together, these findings suggest that the α3β1 integrin dimer
plays a role in adhesion of metastatic cells to the metastasis-associated ECM molecules and
in metastatic seeding.
Galectin-3/8 are present in human lung cancer metastases
Based on the in vitro adhesion data and in vivo mouse findings, we sought to explore the
role of the metastasis-associated ECM molecules in human samples. Using Oncomine32, a
human genetic dataset analysis tool, we examined the correlation of ECM gene expression
and disease severity (e.g. clinical stage or the presence of metastases). Results of these
queries demonstrate that increased expression of LGALS3 or LGALS8 (galectin-3 and
galectin-8, respectively) correlate with increased clinical stage or the presence of metastases
(Fig. 8a). We next investigated whether galectin-3 protein is present at higher levels in
malignant human lung tumors compared to benign non-neoplastic human lung tissue using
samples taken from lungs and lymph nodes of patients. Staining for galectin-3 in human
tissue microarrays revealed a higher presence of the molecule in lymph nodes of patients
with malignant disease (88%) compared to those without cancer (38%) (Fig. 8b).
Furthermore, there was a higher fraction of galectin-3-positive lymph nodes (88%) than
positive primary lung tumor samples (47%), confirming its association with the metastatic
site over the primary tumor (P < 0.05, Fisher’s Exact Test). Thus, the ECM microarrays
were capable of identifying interactions associated with metastasis in human lung cancer.
DISCUSSION
Our ECM microarrays provide a high-throughput multiplexed platform capable of
measuring a variety of cellular responses to ECM. Here, we show they are capable of
identifying adhesion patterns that differentiate metastatic populations from primary tumors.
We found that metastatic lung cancer cells preferentially bind to fibronectin in combination
with laminin, galectin-3, or galectin-8 compared to cells derived from primary tumors.
These changes in adhesion correlate with changes in surface presentation of various
integrins. In particular, α3β1 mediates adhesion to these molecules in vitro and permits
metastatic seeding in vivo. Furthermore, metastases derived from both a genetically-
engineered mouse lung cancer model and from human lung cancers express the metastasis-
associated ECM molecules. It is worth noting that the combinations of these ECM
components elicited the strongest effects, highlighting the importance of using a platform
that is capable of measuring responses to more than individual molecules.
Galectins are a class of lectins that bind β-galactosides and can associate with other ECM
molecules such as fibronectin33. Galectin-3 is associated with metastasis in a variety of
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cancers34–35 and can bind to the oncofetal Thomsen-Friedenreich antigen, a carbohydrate
antigen overexpressed by many carcinomas36. Our platform confirmed its importance in
lung adenocarcinoma, and also identified galectin-8 as having similar importance. While
galectin-8 is known to affect adhesion of cells to other matrix molecules, its role in cancer
and metastasis has been less clear as it has been found to have both a positive and negative
association with adhesion and tumorigenesis37–38. Using the ECM microarrays, we showed
that binding to galectin-8 in combination with fibronectin is strongly associated with
metastatic progression in lung adenocarcinoma.
Furthermore, in addition to many collagens, we found that loss of adhesion to osteopontin
accompanied metastatic progression (Supplementary Fig. S3a–c). Osteopontin levels
correlate with prognosis in patients with metastatic disease39, and secretion of osteopontin
by primary tumors results in mobilization of bone marrow-derived stromal precursors that
help establish the metastatic niche40. In addition to confirming the presence of the metastatic
molecules at the sites of metastases, we found that the invasive portions of primary tumors
and the invasive front of the metastases secrete osteopontin (Supplementary Fig. S5b). A
metastatic tumor line also produces more osteopontin than its corresponding primary (Fig.
5a). These findings suggest that while some primary tumors may activate bone marrow cells
by secreting osteopontin, in our model metastatic cells may contribute to this recruitment at
a comparable or higher level than the instigating primaries, despite their own loss of
adhesion to the immobilized molecule.
The use of gene expression signatures for patient stratification in the clinic has become more
widespread41–45, but while genomic approaches have been beneficial for identifying
candidate genes, the diversity of findings makes the development of broad therapeutic
options seem nearly impossible. By assaying for conserved mechanisms at the phenotypic
level, however, relevant targets can be identified and therapeutics can be developed for a
broad spectrum of patients. Our results highlight the utility of phenotypic screening
approaches for identifying clinical biomarkers. While we identify α3β1 integrin as a
therapeutic target, we also demonstrate that the adhesion signatures generated by the ECM
microarrays are capable of differentiating between genetically similar populations with
varying metastatic potential. Furthermore, no increase in the mRNA levels of the galectins
or their receptors was observed by gene expression microarrays in the M lines (Fig. 5 and
ref29), despite the association of these molecules with metastasis. The presence of galectin-3
and galectin-8 in human samples (Fig. 8) demonstrates the relevance of this platform to
human disease, and thus, we envision that these arrays may be a useful clinical tool for
stratification of cancer patients beyond traditional TNM staging.
The value of the ECM microarray platform extends beyond the specific application of
cancer metastasis. While this study documents the ability to profile adhesion patterns, cells
bound to the arrays can be kept in culture for multiple days to monitor long-term responses
to ECM such as cell death, proliferation, and alterations in gene or protein expression.
Toward that end, one could use multiplexed antibody staining to probe the effects of ECM
on stem cell differentiation or activation. Orthogonal screens can be performed to look at the
effects of growth factors, small molecules, or RNA-interference agents in the context of
ECM. Reduction of requisite cell numbers can be achieved using miniaturized arrays to
screen rare cell populations such as circulating tumor cells or cancer stem cells and to help
expand those populations in vitro for further biological studies. Overall, the ECM
microarrays will enhance our ability to study a host of questions as they pertain to both basic
biological and clinical settings.
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METHODS
Murine Lung Adenocarcinoma cell lines
Cell lines have been described29. Briefly, tumor initiation was achieved using intratracheal
injection of lentiviral Cre recombinase. Tumors were resected, digested, and plated onto
tissue culture treated plastic to generate cell lines29. Cell lines were subsequently cultured in
DMEM, 10% FBS, penicillin/streptomycin, and glutamine. These lines were derived from
both primary lung tumors and their metastases. See Supplementary Table S2 for
nomenclature regarding cell line origins.
Cell Transplantation Assays
All animal procedures were performed in accordance with the MIT Institutional Animal
Care and Use Committee under protocol 0211-014-14. Cell injection studies were performed
in B6129SF1/J mice (Jackson Laboratory, Stock Number 101043). Intrasplenic injections
were performed using 5×105 cells resuspended in 100µL of PBS and injected into the tip of
the spleen following existing protocols29. Animals were anesthetized with avertin prior to
surgery. Fur was removed from the animals and they were sterilized with Betadine and 70%
ethanol. The spleen was exteriorized following incisions in the skin and body wall. Cells
were injected into the end of the spleen with a 27gauge syringe and allowed to travel into
circulation for two minutes. Spleens were then excised from the animals following
cauterization of the splenic vessels. The muscle wall was closed using 5-0 dissolvable
sutures, and the skin was closed using 7mm wound clips (Roboz). Mice were euthanized
2.5-4 weeks following injection, and their livers were excised. Quantification of surface
nodules and imaging of livers was performed using a dissection microscope. Tissues were
embedded in paraffin following fixation in 4% paraformaldehyde and stained using
hematoxylin and eosin.
Extracellular Matrix Microarrays Preparation
Vantage acrylic slides (CEL Associates VACR-25C) were coated with polyacrylamide by
depositing prepolymer containing Irgacure 2959 photoinitiator (Ciba) between the slide and
a glass coverslip22. Following polymerization, slides were soaked in ddH2O and the
coverslips were removed. Slides were allowed to dry prior to molecule deposition. Slides
were spotted using a DNA Microarray spotter (Cartesian Technologies Pixsys Microarray
Spotter and ArrayIt 946 Pins). 768 combinations were spotted in replicates of five.
Rhodamine dextran (Invitrogen) was spotted as negative controls and for use in image
alignment. The following molecules were used: Collagen I (Millipore), Collagen II
(Millipore), Collagen III (Millipore), Collagen IV (Millipore), Collagen V (BD
Biosciences), Collagen VI (BD Biosciences), Fibronectin (Millipore), Laminin (Millipore),
Merosin (Millipore), Tenascin-R (R&D Systems), Chondroitin Sulfate (Millipore),
Aggrecan (Sigma), Elastin (Sigma), Keratin (Sigma), Mucin (Sigma), Superfibronectin
(Sigma), F-Spondin (R&D Systems), Nidogen-2 (R&D Systems), Heparan Sulfate (Sigma),
Biglycan (R&D Systems), Decorin (R&D Systems), Galectin 1 (R&D Systems), Galectin 3
(R&D Systems), Galectin 3c (EMD Biosciences), Galectin 4 (R&D Systems), Galectin 8
(R&D Systems), Thrombospondin-4 (R&D Systems), Osteopontin (R&D Systems),
Osteonectin (R&D Systems), Testican 1 (R&D Systems), Testican 2 (R&D Systems), Fibrin
(Sigma), Tenascin-C (R&D Systems), Nidogen-1 (R&D Systems), Vitronectin (R&D
Systems), Rat Agrin (R&D Systems), Hyaluronan (R&D Systems), Brevican (R&D
Systems). The laminin used is Millipore Catalog No. AG56P, and is a mixture of human
laminins that contain the beta1 chain. Source plates used in the spotter were prepared using a
Tecan liquid handler. Molecules were prepared at a concentration of 200µg/mL using a
buffer described previously 22. Slides were stored in a humidity chamber at 4°C prior to use.
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Extracellular Matrix Microarray Seeding and Analysis
Slides were washed in PBS and treated with UV prior to seeding cells. They were placed in
a seeding device that holds the top surface of the slides flush with bottom of the well.
400,000 cells were seeded on each slide in 6mL of serum-free medium (DMEM and
penicillin/streptomycin). Cells were allowed to attach for two hours at 37°C. After
attachment, slides were washed three times, transferred to quadriperm plates (NUNC,
167063), and new medium was added (DMEM, 10%FBS, penicillin/streptomycin, and
glutamine). Slides were left at 37°C for two additional hours prior to removal for staining.
Slides were washed twice with PBS and fixed with 4% paraformaldehyde. Nuclei were
stained using Hoechst (Invitrogen) in combination with 0.1% Triton-X and PBS. Slides were
mounted with Fluoromount-G (Southern Biotech 0100-01) and stored at 4°C prior to
imaging. Slides were imaged using a Nikon Ti-E inverted fluorescence microscope and NIS
Elements Software (Nikon). The entire slide was scanned and images stitched using that
software. Image manipulation and analysis was performed in MATLAB (Mathworks) and
quantification of nuclei was performed using CellProfiler30. Clustering analysis was
performed using Spotfire (Tibco). Replicate spots on each slide were averaged and those
whose values were greater than one standard deviation above or below the mean of the
replicates were excluded. Slides were normalized to the mean of their non-zero adhesion
values. Clustering was performed based on Euclidean distances using Spotfire (TIBCO)
with the Hierarchical Clustering algorithm (normalized adhesion > 0.01).
In vitro Adhesion Seeding
in vitro ECM adhesion tests were performed using 96-well-plates (Corning 3603). Plates
were coated with 20µg/mL of fibronectin alone or 20µg/mL of fibronectin and 20µL/mL of
the second molecule in PBS overnight at 4°C. Plates were then blocked with 1wt% BSA at
room temperature for 1hr. Plates were allowed to dry prior to adding 2×104 cells/well in
warm serum-free DMEM. Cells were allowed to adhere for 1hr at 37°C and shaken every
15minutes to ensure uniform seeding. Cells were washed, fixed with 4% paraformaldehyde,
and stained with Hoechst (invitrogen). Wells were imaged using a Nikon Ti-E inverted
epifluorescent microscope and analyzed with Nikon Elements software.
Protein Analysis
Western blot analysis of ECM molecules was performed with the following antibodies:
galectin-3 (Abcam ab53082, 1:500), galectin-8 (Abcam ab69631, 1:500), osteopontin
(Abcam ab8448, 1:2000), fibronectin (Abcam ab2413, 1:1000), laminin (Abcam b11575,
1:1000), collagen I (Abcam ab34710, 1:5000), and α-tubulin (Cell Signaling 2125, 1:1000).
Immunohistochemistry of ECM molecules was performed with the following antibodies:
galectin-3 (Abcam ab53082, 1:500), galectin-8 (Abcam ab69631, 1:75), osteopontin (Abcam
ab8448, 1:200), laminin (Abcam ab11575, 1:100), fibronectin (Millipore AB2033, 1:80),
Hmga2 (Biocheck 59170AP, 1:1000), collagen I (Abcam ab34710, 1:500),collagen VI
(Abcam ab6588, 1:100). Integrin staining was performed using the following antibodies:
integrin αv (Millipore AB1930, 1:200), integrin α5 (Chemicon AB1928, 1:200), integrin α3
antibody was a gift from JML. Tissue microarrays were acquired from LifeSpan Biosciences
(LS-SLUCA50), and were stained with the same galectin-3 antibody. Murine tissues were
harvested from KrasLSL-G12D, p53flox/flox mice27–29. IHC was performed following
resection from mice, fixation in formalin, and embedding in paraffin. Flow cytometry
analysis of integrin expression was performed using the following antibodies: integrin α5
(Abcam and BioLegend-clone 5H10-27, 1:100), integrin αv (BD-clone RMV-7, 1:100),
integrin α6 (BD and BioLegend-clone GoH3, 1:100), integrin α3 (R&D, 1:100), integrin α1
(BD-clone Ha31/8 and BioLegend-clone HMα1, 1:100) and integrin α2 (BD-clone HMα2,
1:100).
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RNA Isolation and Expression Profiling
Cell lysates were harvested using Trizol (Sigma). Chloroform extraction was performed
followed by RNA purification using Qiagen RNeasy spin columns. Lysates were analyzed
for RNA integrity and prepared with Affymetrix GeneChip WT Sense Target Labelling and
Control Reagents kit, followed by hybridization to Affymetrix Mouse 3’ Arrays (Mouse
430A 2.0) Lysates used for gene expression microarrays were harvested at the same time as
the ECM microarrays were seeded to ensure minimal variability introduced by cell culture.
R/Bioconductor software was used to process array images. Unsupervised hierarchical
clustering analysis was performed in Spotfire (Tibco) for all probesets with variance>0.5
and expression>3.0 using Euclidean distances. Datasets are publically available from NCBI
under accession number GSE40222.
Retroviral shRNA Constructs
miR30-based shRNAs targeting integrins β1
(TGCTGTTGACAGTGAGCGCGGCTCTCAAACTATAAAGAAATAGTGAAGCCACA
GATGTATTTCTTTATAGTTTGAGAGCCTTGCCTACTGCCTCGGA), α3
(TGCTGTTGACAGTGAGCGCCGGATGGACATTTCAGAGAAATAGTGAAGCCACA
GATGTATTTCTCTGAAATGTCCATCCGTTGCCTACTGCCTCGGA), or control firefly
luciferase
(AAGGTATATTGCTGTTGACAGTGAGCGAGCTCCCGTGAATTGGAATCCTAGTGA
AGCCACAGATGTAGGATTCCAATTCAGCGGGAGCCTGCCTACTGCCTCG) were
designed using the shRNA retriever software (http://katahdin.cshl.edu/homepage/siRNA/
RNAi.cgi?type=shRNA), synthesized (IDT, Coralville, Iowa), and then cloned into the
MSCV-ZSG-2A-Puro-miR30 vector48. Packaging of retrovirus and transduction of cells was
done as described previously49.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Extracellular Matrix Microarray Platform Presents Combinations of ECM Molecules
for Cell Attachment
(a) ECM microarrays are generated by spotting nearly 800 unique combinations of ECM
molecules on glass slides coated with polyacrylamide followed by seeding of cells onto the
slides. (b) Polyacrylamide acts to entrap molecules of a large range of molecular weights. (c)
Verification of presentation of all molecules by immunolabeling (colored spots) or NHS-
fluorescein labeling (grayscale spots) of all molecules subsequent to array generation and
rehydration. (d) Representative images of cells adhered to ECM spots demonstrating
selective adhesion in the locations of ECM. Scale bar on five-spot image is 200µm. Scale
bars on single-spot images are 50µm.
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Figure 2. Combinatorial Adhesion Profiles are generated using ECM microarrays
(a) Nuclear stain of cells seeded on the ECM microarrays. (b) Identification of individual
nuclei on one spot using CellProfiler30. (c) Quantification of adhesion to all molecule
combinations for one cell line. (d) Selected adhesion profiles for three molecules: Collagen I
(blue), Collagen IV (green), and Fibronectin (red) in combination with all other molecules.
Dashed blue lines represent adhesion to that molecule alone. Arrows denote combinations
with the other two molecules or alone. Error bars are s.e.m. of three replicate slides. (e)
Comparisons of three replicate slides for two representative cell lines. Scale bars in (a) and
(b) are 450µm and 100µm, respectively.
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Figure 3. ECM Microarrays identify key adhesive changes in metastatic progression
(a) Unsupervised hierarchical clustering of adhesion profiles generated by the ECM
microarrays. Vertical axis represents different ECM combinations. Horizontal axis
represents different cell lines. Yellow bars indicate primary tumors (TnonMet and TMet lines).
Red bars indicate nodal (N) or distant metastases (M). (b) Average adhesion of metastatic
cell lines (M) to each combination compared to those of the metastatic primary tumor cell
lines (TMet). (c) Comparison of 393M1 adhesion for each combination to its matching
primary tumor line, 393T5. Red dots indicate top ECM combinations exhibiting preferential
adhesion by metastatic lines over the metastatic primary tumor lines. (d) Top three
combinations exhibiting the greatest increase in adhesion across tumor progression as
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represented by the four classes of cell lines (TnonMet, TMet, N, and M). Error bars in (d) are
s.e.m. of the different cell lines of each class (n = 3 cell lines per class) with the exception of
the M class where there are two lines, and thus the error bars are the range of the means.
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Figure 4. Metastasis-associated ECM molecules are present in the sites of metastases but not
primary tumors
Immunostaining of the metastasis-associated ECM molecules in the lungs, lymph nodes, and
distant metastases of mice bearing endogenous lung adenocarcinomas
(KrasLSL-G12D/+;p53flox/flox mice). Insets are magnified views of boxed areas showing ECM
molecule fibrils. Number of tissues examined for each organ: Lungs: 10; lymph nodes: 5;
livers/kidneys: 22. ‘T’: tumor. Dotted line depicts edge of tumor and normal kidney. Scale
bars are 50µm.
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Figure 5. ECM production and integrin mRNA expression by cell lines have minimal correlation
with adhesion
(a) Western blot analysis of the metastasis- and primary tumor-associated ECM molecules
produced by the 393T5 (TMet) and 393M1 (M) cell lines. (b) Comparison of ECM adhesion
for all cell lines to gene expression of the cognate integrins from gene expression microarray
data. (c) Integrin subunit mRNA expression from Affymetrix microarray analysis in 393T5
and 393M1 cell lines.
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Figure 6. Integrin Surface Expression Correlates with ECM binding profiles
(a) Flow cytometry of integrin surface expression in 393T5 (TMet) and 393M1 (M) cell
lines. Integrin subunits that bind to metastasis-associated molecules show increased surface
presentation in the metastatic line (α5, αv, α6, α3), while those that bind to primary tumor-
associated molecules show decreased presentation (α1 and α2). (b) IHC for metastasis-
associated integrins in mice bearing autochthonous tumors with spontaneous metastases to
the liver and lymph nodes. Scale bars are 100µm.
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Figure 7. Integrin α3β1 mediates adhesion and seeding in vitro and in vivo
(a) in silico network mapping using GeneGO (MetaCore) generates the Lung
Adenocarcinoma Metastasis Network. Analysis of the network reveals that integrin a3b1 is
the surface receptor with the most edges (a). Knockdown of both α3 and β1 integrin subunits
by shRNA reduces adhesion to metastasis-associated molecules in vitro (b) and prevents
metastatic seeding in vivo (c-e). shFF is the control hairpin targeting firefly luciferase. One-
way ANOVA with Tukey’s Multiple Comparison Test was used to analyze the data in figure
(b). Error bars in (b) represent standard error (n = 3). (c) Number of liver tumor nodules of
the surface of livers 2.5 weeks after intrasplenic injection. Mann-Whitney (non-parametric)
test was used to analyze significance. (d) Fluorescence imaging of whole livers after
resection. Cell lines express nuclear-excluded ZSGreen. Scale bars are 0.5cm. (f)
Hematoxylin and eosin stain of liver slices. Scale bars are 2mm. Blue data points in (d)
correspond to images in (e) and (f). All results shown are representative of multiple
independent experiments.
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Figure 8. Metastasis-associated molecules are present in the metastases of human lung cancers
(a-d) Oncomine32 results for human lung cancer expression of LGALS3 and LGALS8. (a)
LGALS3 Expression in Hou Lung: Large Cell Lung Carcinoma – Advanced Stage. (b)
LGALS3 Expression in Bild Lung: Lung Adenocarcinoma – Advanced Stage. (c) LGALS8
Expression in Hou Lung: Large Cell Lung Carcinoma – Advanced Stage. (d) LGALS8 Copy
Number in TCGA Lung 2: Lung Adenocarcinoma – Advanced M Stage. LGALS3 and
LGALS8 are overexpressed in Stage II lung cancer compared to stage I (P = 0.018 and
9.72E-4, respectively)(a,c). Microarray data source GSE1918846. (b) LGALS3 is
overexpressed in Stage IV lung cancer compared to other stages (P = 0.040). Microarray
data source GSE314147. (d) LGALS8 has increased copy number in advanced M stage lung
cancer (P = 0.013) in the “Lung Carcinoma DNA Copy Number Data” dataset available
from The Cancer Genome Atlas website (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).
(e) Representative images of human tissue microarray staining results for galectin-3
presence or absence in the primary sites and lymph nodes. Scale bars are 500µm. Box and
whisker plots in (a-d): dots represent maximum and minimum values, whiskers show 90th
and 10th percentiles, boxes show 75th and 25 percentiles, and line shows median. P-values in
(a-d) were computed by Oncomine software using Student’s t-test (a, c-d) or Pearson’s
correlation analysis (b).
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